BRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR

Reuters

Yesterday

BRIEF-<a href="https://laohu8.com/S/HUMDF">Hua Medicine</a> Says Dorzagliatin Approved For Marketing In Hong Kong SAR

March 3 (Reuters) - Hua Medicine 2552.HK:

APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINA
DORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINA

Further company coverage: 2552.HK

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616393868"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616393868\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616393868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 08:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616393868","market":"nz","top_or_hot":-1,"title":"BRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HUMDF\">Hua Medicine</a> Says Dorzagliatin Approved For Marketing In Hong Kong SAR</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Hua Medicine <span>2552.HK</span>:</p><ul><li><p>APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINA</p></li><li><p>DORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINA</p></li></ul><p>Further company coverage: <span>2552.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-03 08:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HUMDF\">Hua Medicine</a> Says Dorzagliatin Approved For Marketing In Hong Kong SAR</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Hua Medicine <span>2552.HK</span>:</p><ul><li><p>APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINA</p></li><li><p>DORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINA</p></li></ul><p>Further company coverage: <span>2552.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZQ1PJ:1","article_id":"2616393868","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616393868","pubTimestamp":1772498620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SARMarch 3  - Hua Medicine 2552.HK:APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINADORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINAFurther company coverage: 2552.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B","BK1191":"制药","BK1574":"生物医药B类股"},"translate_title":"简介-华领医药称Dorzagliatin在香港特区获批上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":0.9},"content_text":"BRIEF-Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SARMarch 3 (Reuters) - Hua Medicine 2552.HK:APPROVAL OF DORZAGLIATIN FOR MARKETING IN CHINADORZAGLIATIN APPROVED FOR MARKETING BY PHARMACEUTICAL SERVICE OF DEPARTMENT OF HEALTH OF HONG KONG SAR OF CHINAFurther company coverage: 2552.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}